Metagenomi, Inc.
MGX
$2.07
$0.136.70%
| Weiss Ratings | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.61% | |||
| 30-Day Total Return | -30.30% | |||
| 60-Day Total Return | 11.89% | |||
| 90-Day Total Return | 7.81% | |||
| Year to Date Total Return | -45.38% | |||
| 1-Year Total Return | -82.75% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -84.30% | |||
| 52-Week Low % Change | 20.50% | |||
| Price | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $12.36 | |||
| 52-Week Low Price | $1.61 | |||
| 52-Week Low Price (Date) | Nov 20, 2024 | |||
| 52-Week High Price (Date) | Mar 07, 2024 | |||
| Valuation | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 72.60M | |||
| Enterprise Value | -155.91M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -7.66 | |||
| Earnings Per Share Growth | -53.24% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.29 | |||
| Price/Book (Q) | 0.28 | |||
| Enterprise Value/Revenue (TTM) | -2.83 | |||
| Price | $2.07 | |||
| Enterprise Value/EBITDA (TTM) | 1.87 | |||
| Enterprise Value/EBIT | 1.76 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 36.77M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 871 4880 | |||
| Address | 5959 Horton Street EmeryVille, CA 94608 | |||
| Website | www.metagenomi.co | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -160.62% | |||
| Profit Margin | -134.26% | |||
| Management Effectiveness | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -14.85% | |||
| Return on Equity | -- | |||
| Income Statement | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 55.08M | |||
| Total Revenue (TTM) | 55.08M | |||
| Revenue Per Share | $1.50 | |||
| Gross Profit (TTM) | -55.69M | |||
| EBITDA (TTM) | -83.33M | |||
| EBIT (TTM) | -88.47M | |||
| Net Income (TTM) | -73.95M | |||
| Net Income Avl. to Common (TTM) | -73.95M | |||
| Total Revenue Growth (Q YOY) | -6.87% | |||
| Earnings Growth (Q YOY) | 5.28% | |||
| EPS Diluted (TTM) | -7.66 | |||
| EPS Diluted Growth (Q YOY) | 91.23% | |||
| Balance Sheet | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 274.59M | |||
| Cash Per Share (Q) | $7.47 | |||
| Total Current Assets (Q) | 282.29M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 255.77M | |||
| Current Ratio (Q) | 6.178 | |||
| Book Value Per Share (Q) | $6.83 | |||
| Total Assets (Q) | 358.35M | |||
| Total Current Liabilities (Q) | 45.69M | |||
| Total Debt (Q) | 46.07M | |||
| Total Liabilities (Q) | 102.58M | |||
| Total Common Equity (Q) | 255.77M | |||
| Cash Flow | MGX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -56.07M | |||
| Cash from Financing (TTM) | 82.68M | |||
| Net Change in Cash (TTM) | -76.78M | |||
| Levered Free Cash Flow (TTM) | -65.55M | |||
| Cash from Operations (TTM) | -103.39M | |||
